Cargando…
PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer
Recurrent disease emerges in the majority of patients with ovarian cancer (OVCA). Adoptive T-cell therapies with T-cell receptors (TCRs) targeting tumor-associated antigens (TAAs) are considered promising solutions for less-immunogenic ‘cold’ ovarian tumors. In order to treat a broader patient popul...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070997/ https://www.ncbi.nlm.nih.gov/pubmed/37026005 http://dx.doi.org/10.3389/fimmu.2023.1121973 |
_version_ | 1785019104725303296 |
---|---|
author | van Amerongen, Rosa A. Tuit, Sander Wouters, Anne K. van de Meent, Marian Siekman, Sterre L. Meeuwsen, Miranda H. Wachsmann, Tassilo L. A. Remst, Dennis F. G. Hagedoorn, Renate S. van der Steen, Dirk M. de Ru, Arnoud H. Verdegaal, Els M. E. van Veelen, Peter A. Falkenburg, J. H. Frederik Heemskerk, Mirjam H. M. |
author_facet | van Amerongen, Rosa A. Tuit, Sander Wouters, Anne K. van de Meent, Marian Siekman, Sterre L. Meeuwsen, Miranda H. Wachsmann, Tassilo L. A. Remst, Dennis F. G. Hagedoorn, Renate S. van der Steen, Dirk M. de Ru, Arnoud H. Verdegaal, Els M. E. van Veelen, Peter A. Falkenburg, J. H. Frederik Heemskerk, Mirjam H. M. |
author_sort | van Amerongen, Rosa A. |
collection | PubMed |
description | Recurrent disease emerges in the majority of patients with ovarian cancer (OVCA). Adoptive T-cell therapies with T-cell receptors (TCRs) targeting tumor-associated antigens (TAAs) are considered promising solutions for less-immunogenic ‘cold’ ovarian tumors. In order to treat a broader patient population, more TCRs targeting peptides derived from different TAAs binding in various HLA class I molecules are essential. By performing a differential gene expression analysis using mRNA-seq datasets, PRAME, CTCFL and CLDN6 were selected as strictly tumor-specific TAAs, with high expression in ovarian cancer and at least 20-fold lower expression in all healthy tissues of risk. In primary OVCA patient samples and cell lines we confirmed expression and identified naturally expressed TAA-derived peptides in the HLA class I ligandome. Subsequently, high-avidity T-cell clones recognizing these peptides were isolated from the allo-HLA T-cell repertoire of healthy individuals. Three PRAME TCRs and one CTCFL TCR of the most promising T-cell clones were sequenced, and transferred to CD8+ T cells. The PRAME TCR-T cells demonstrated potent and specific antitumor reactivity in vitro and in vivo. The CTCFL TCR-T cells efficiently recognized primary patient-derived OVCA cells, and OVCA cell lines treated with demethylating agent 5-aza-2′-deoxycytidine (DAC). The identified PRAME and CTCFL TCRs are promising candidates for the treatment of patients with ovarian cancer, and are an essential addition to the currently used HLA-A*02:01 restricted PRAME TCRs. Our selection of differentially expressed genes, naturally expressed TAA peptides and potent TCRs can improve and broaden the use of T-cell therapies for patients with ovarian cancer or other PRAME or CTCFL expressing cancers. |
format | Online Article Text |
id | pubmed-10070997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100709972023-04-05 PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer van Amerongen, Rosa A. Tuit, Sander Wouters, Anne K. van de Meent, Marian Siekman, Sterre L. Meeuwsen, Miranda H. Wachsmann, Tassilo L. A. Remst, Dennis F. G. Hagedoorn, Renate S. van der Steen, Dirk M. de Ru, Arnoud H. Verdegaal, Els M. E. van Veelen, Peter A. Falkenburg, J. H. Frederik Heemskerk, Mirjam H. M. Front Immunol Immunology Recurrent disease emerges in the majority of patients with ovarian cancer (OVCA). Adoptive T-cell therapies with T-cell receptors (TCRs) targeting tumor-associated antigens (TAAs) are considered promising solutions for less-immunogenic ‘cold’ ovarian tumors. In order to treat a broader patient population, more TCRs targeting peptides derived from different TAAs binding in various HLA class I molecules are essential. By performing a differential gene expression analysis using mRNA-seq datasets, PRAME, CTCFL and CLDN6 were selected as strictly tumor-specific TAAs, with high expression in ovarian cancer and at least 20-fold lower expression in all healthy tissues of risk. In primary OVCA patient samples and cell lines we confirmed expression and identified naturally expressed TAA-derived peptides in the HLA class I ligandome. Subsequently, high-avidity T-cell clones recognizing these peptides were isolated from the allo-HLA T-cell repertoire of healthy individuals. Three PRAME TCRs and one CTCFL TCR of the most promising T-cell clones were sequenced, and transferred to CD8+ T cells. The PRAME TCR-T cells demonstrated potent and specific antitumor reactivity in vitro and in vivo. The CTCFL TCR-T cells efficiently recognized primary patient-derived OVCA cells, and OVCA cell lines treated with demethylating agent 5-aza-2′-deoxycytidine (DAC). The identified PRAME and CTCFL TCRs are promising candidates for the treatment of patients with ovarian cancer, and are an essential addition to the currently used HLA-A*02:01 restricted PRAME TCRs. Our selection of differentially expressed genes, naturally expressed TAA peptides and potent TCRs can improve and broaden the use of T-cell therapies for patients with ovarian cancer or other PRAME or CTCFL expressing cancers. Frontiers Media S.A. 2023-03-21 /pmc/articles/PMC10070997/ /pubmed/37026005 http://dx.doi.org/10.3389/fimmu.2023.1121973 Text en Copyright © 2023 van Amerongen, Tuit, Wouters, van de Meent, Siekman, Meeuwsen, Wachsmann, Remst, Hagedoorn, van der Steen, de Ru, Verdegaal, van Veelen, Falkenburg and Heemskerk https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology van Amerongen, Rosa A. Tuit, Sander Wouters, Anne K. van de Meent, Marian Siekman, Sterre L. Meeuwsen, Miranda H. Wachsmann, Tassilo L. A. Remst, Dennis F. G. Hagedoorn, Renate S. van der Steen, Dirk M. de Ru, Arnoud H. Verdegaal, Els M. E. van Veelen, Peter A. Falkenburg, J. H. Frederik Heemskerk, Mirjam H. M. PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer |
title | PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer |
title_full | PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer |
title_fullStr | PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer |
title_full_unstemmed | PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer |
title_short | PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer |
title_sort | prame and ctcfl-reactive tcrs for the treatment of ovarian cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070997/ https://www.ncbi.nlm.nih.gov/pubmed/37026005 http://dx.doi.org/10.3389/fimmu.2023.1121973 |
work_keys_str_mv | AT vanamerongenrosaa prameandctcflreactivetcrsforthetreatmentofovariancancer AT tuitsander prameandctcflreactivetcrsforthetreatmentofovariancancer AT woutersannek prameandctcflreactivetcrsforthetreatmentofovariancancer AT vandemeentmarian prameandctcflreactivetcrsforthetreatmentofovariancancer AT siekmansterrel prameandctcflreactivetcrsforthetreatmentofovariancancer AT meeuwsenmirandah prameandctcflreactivetcrsforthetreatmentofovariancancer AT wachsmanntassilola prameandctcflreactivetcrsforthetreatmentofovariancancer AT remstdennisfg prameandctcflreactivetcrsforthetreatmentofovariancancer AT hagedoornrenates prameandctcflreactivetcrsforthetreatmentofovariancancer AT vandersteendirkm prameandctcflreactivetcrsforthetreatmentofovariancancer AT deruarnoudh prameandctcflreactivetcrsforthetreatmentofovariancancer AT verdegaalelsme prameandctcflreactivetcrsforthetreatmentofovariancancer AT vanveelenpetera prameandctcflreactivetcrsforthetreatmentofovariancancer AT falkenburgjhfrederik prameandctcflreactivetcrsforthetreatmentofovariancancer AT heemskerkmirjamhm prameandctcflreactivetcrsforthetreatmentofovariancancer |